Several other brokerages have also issued reports on HCM. ValuEngine raised shares of HUTCHISON CHINA/S from a hold rating to a buy rating in a research note on Thursday, August 1st. Macquarie assumed coverage on shares of HUTCHISON CHINA/S in a research note on Friday, July 5th. They issued an outperform rating on the stock. Finally, Zacks Investment Research raised shares of HUTCHISON CHINA/S from a hold rating to a buy rating and set a $24.00 target price on the stock in a research note on Wednesday, July 10th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. HUTCHISON CHINA/S presently has an average rating of Buy and a consensus target price of $25.41.
Shares of NASDAQ HCM opened at $19.81 on Friday. The company has a market cap of $2.68 billion, a price-to-earnings ratio of -34.75 and a beta of 0.70. The company has a quick ratio of 4.19, a current ratio of 4.33 and a debt-to-equity ratio of 0.06. HUTCHISON CHINA/S has a 1 year low of $19.37 and a 1 year high of $39.68. The company has a 50-day simple moving average of $22.98.
HUTCHISON CHINA/S Company Profile
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Recommended Story: Is it Safe to Invest in Commodities?
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.